Sarepta price target raised to $169 from $164 at BofA

BofA raised the firm’s price target on Sarepta to $169 from $164 and keeps a Buy rating on the shares after the company announced the acceptance of the efficacy supplement to expand the Elevidys label in Duchenne muscular dystrophy. The firm thinks that the review goal date of June 21 reinforces management commentary on the FDA’s commitment to an expediated review.